Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact
Shorla Oncology

SH-105 Successful FDA pre-IND meeting

March 7th 2022June 14th 2019

Read More

Photo

American Society of Clinical Oncologists (ASCO) Annual Meeting 2019, Chicago, USA

March 7th 2022June 4th 2019

Read More

MIT

Shorla attending MIT-Harvard Medical School Healthcare Innovation Bootcamp, Boston, USA

April 15th 2021May 7th 2019

Read More

Photo

Shorla Oncology meet Nancy Pelosi, Madam Speaker of the US House of Representatives

March 7th 2022May 7th 2019

Read More

Photo

Shorla Oncology attend Harvard Business School 19th annual Healthcare conference, Boston, USA

March 7th 2022November 20th 2018

Read More

Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

STATE COMPLIANCE PROGRAM DECLARATIONS

Company number: 618033
©SHORLA ONCOLOGY® 2026

© 2026 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.